Glycans have multiple roles in the viral entry process, and blocking the glycosylation modification of O-glycans using a glycobiological approach effectively inhibits the viral entry process. At CD BioGlyco, we provide blocking O-glycan-protein interaction inhibitor development service.
We provide various types of blocking O-glycan-protein interaction inhibitor development services. At the same time, we also modify, optimize, and evaluate the effect of the inhibitors to ensure that the inhibitors we developed have good inhibitory activity.
Fig.1 Blocking O-glycan-protein interaction inhibitor development service. (CD BioGlyco)
Technology: Blocking the processing of O-glycans
Results: The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its receptor-binding domain (RBD), and its primary receptor angiotensin-converting enzyme 2 (ACE2) are extensively glycosylated. The authors observed that the contribution of N- and O-glycans to Spike-ACE2 binding was minimal. However, these carbohydrates play an important role in regulating viral entry. Blocking N-glycan biosynthesis at the oligomannose stage using a genetic approach and the small molecule kifunensine significantly reduced viral entry into ACE2-expressing HEK293T cells. Blocking O-glycan processing also partially blocked viral entry. Mechanistic studies showed that glycans have multiple roles in viral entry. Among them, inhibition of N-glycan biosynthesis enhanced spike protein hydrolysis. This reduces viral presentation to the RBD, decreases binding to host ACE2, and reduces viral entry. Overall, inhibitors of glycosylation chemistry can be evaluated against coronavirus disease 2019 (COVID-19).
CD BioGlyco has been dedicated to the Development of Glycosylation Inhibitors for many years and has achieved great progress. We have developed several aspects in the field of O-Glycosylation Inhibitor Development Services. Our team ensures high quality at every step. To learn more about our R&D services, please feel free to contact us.